title: Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis.
abstract: Paclitaxel is currently formulated in a vehicle of 50% ethanol and 50% polyethoxylated surfactant cremophor EL. Cremophor EL has been reported to reverse P-glycoprotein-mediated multidrug resistance (MDR) at doses which are clinically achievable. It has also been reported to have a cytotoxic effect per se. In this study we used two different methods to evaluate the survival of cells exposed to paclitaxel with or without cremophor EL and the vehicle alone. Two laryngeal SCC cell lines (UT-SCC-19A and UT-SCC-29) and two ovarian adenocarcinoma cell lines (UT-OC-3 and UT-OC-5) established in our laboratory were investigated. Northern hybridisation was used to study the mdr-1 mRNA expression of the cell lines. With sensitive Northern analyses, these four lines yielded mdr-1 mRNA signals of the expected 4.5 kb size and of variable intensity, generally at higher levels than those in the positive control cell line KB. The 96-well plate clonogenic assay was used to obtain the fraction survival data and apoptosis was recorded by time-lapse video microscopy. Both methods indicate that cremophor EL alone has no effect on cellular survival. Consequently, paclitaxel without cremophor EL is as active as paclitaxel with cremophor EL in vitro.
authors.affiliation: Department of Obstetrics and Gynaecology, Turku University Central Hospital, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Engblom
authors.forename: J O
authors.initials: JO
authors.lastname: Pulkkinen
authors.forename: V
authors.initials: V
authors.lastname: Rantanen
authors.forename: H
authors.initials: H
authors.lastname: Hirvonen
authors.forename: J
authors.initials: J
authors.lastname: Kulmala
authors.forename: R
authors.initials: R
authors.lastname: Grènman
authors.forename: S
authors.initials: S
authors.lastname: Grènman
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D005990:Glycerol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology*; D014677:Pharmaceutical Vehicles; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014410:Tumor Stem Cell Assay / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D014677:Pharmaceutical Vehicles; C000515:cremophor EL; D017239:Paclitaxel; D005990:Glycerol